Industry news that matters to you.  Learn more

Nodality, Inc. Announces Expansion of Company’s Patent Estate Covering Programs to Improve the Treatment of Patients with Severe Diseases in Immunology, Oncology, and Autoimmune Diseases

Reading time: 1 – 2 minutes

Nodality, Inc., a next-generation life sciences company partnering with leading firms to advance precision medicine, announced today the issuance by the United States Patent and Trademark Office (USPTO) of Patent Number 8,394,599, which broadly covers methods for applying the Company’s Single Cell Network Profiling (SCNP) technology. SCNP provides the core foundation for Nodality’s programs dedicated to making medicines better by increasing the productivity of therapeutic R&D programs, enhancing life cycle management for commercialized drugs, and introducing new predictive diagnostics. With the issuance of this patent, Nodality now owns or has exclusive rights to more than 25 issued patents and 80 patent applications.

Laura Brege, President and Chief Executive Officer, commented, “The new patent extends and complements Nodality’s other foundational patents covering SCNP, a uniquely powerful tool for correlating clinical data with functional biology. The patent provides further protection for unique biomarkers of protein activation and cell function in single cells and, importantly, applications of this information in clinical management and therapeutic product development. Through our growing patent estate and partnered programs, Nodality is in a key position to improve the treatment of patients with severe diseases, including in immunology, oncology, and autoimmune diseases.”

Source: Nodality